AzTrials
AzTrials

Mechanical Ventilation ComplicationNUMBERNMESNCT04382378

Effects of NMES in Critically Ill Patients

A study testing neuromuscular electrical stimulation in people with Mechanical Ventilation Complication and Muscle Weakness Condition, run by Escola Superior de Ciencias da Saude at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Muscle wasting occurred early and rapidly in critically ill patients. Early therapeutic strategies to either maintain muscle structure and function should be encouraged. Neuromuscular electrical stimulation (NMES) is an attractive intervention to maintain muscle mass and strength in critically ill patients during the… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
neuromuscular electrical stimulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteBrazil
Study dates
1 Feb 2021to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 18 years or older
  • Intubated and expected to remain invasively mechanically ventilated the day after tomorrow
  • laboratory confirmed COVID-19 (diagnosis of SARS-CoV-2 via reverse transcriptase polymerase chain reaction as per the World Health Organization protocol or by nucleic acid based isothermal amplification)

Who cannot join

  • Dependent for activities of daily living in the month prior to current ICU admission (gait aids are acceptable).
  • Documented cognitive impairment.
  • Proven or suspected spinal cord injury or other neuromuscular disease that will result in permanent or prolonged weakness (not including ICU acquired weakness)
  • Death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision maker are not committed to full active treatment
  • pregnancy
  • patients with unstable fractures in the vertebral column and lower limbs.

Trial locations and contacts

1 site in 1 country.

VINICIUS ZACARIAS MALDANER D SILVA contact

6135462517

viniciusmaldaner@gmail.com

Brazil1 site, 1 recruiting
  • Secretaria de Saúde do Distrito Federal

    Brasília, Federal District, 700000

    Vinicius Silva, PhD, +55 61 20172145, viniciius.maldaner@escs.edu.br

    Recruiting

Other trials in Brazil

About this study

Official title: Effects of Different Regimen Protocols of NMES in COVID 19 Critically Ill Patients

Muscle wasting occurred early and rapidly in critically ill patients. Early therapeutic strategies to either maintain muscle structure and function should be encouraged. Neuromuscular electrical stimulation (NMES) is an attractive intervention to maintain muscle mass and strength in critically ill patients during the first week of ICU stay. This study will test the hypothesis that the number of contraction per day evoked by NMES in the first two weeks of illness may influence in muscle wasting, with beneficial effects on the physical and functional status in mechanically ventilated patients.

Read the detailed description

Patients with prolonged mechanical ventilation require deep sedation and mechanical ventilation, factors predisposing to the development of skeletal muscle wasting and acute muscle atrophy. Strategies to attenuate this process must be used. The neuromuscular electrostimulation (NMES) leads to the application of electrical currents in the skin aiming at muscle contraction, has beneficial effects for the population of critical patients. However, the number of contractions induced by NMES to attenuate the loss of muscle mass in this population is not yet established. This randomized controlled trial with 120 patients that will be randomized to one of the 3 study groups: 100 continuous daily contractions (100Cd), 50 continuous daily contractions (50Cd) and control group. Muscle thickness, NMES-induced strength, and clinical and functional parameters at the time of discharge from the ICU and hospital discharge will be assessed daily. The results of this project will provide an important contribution to the understanding of the mechanisms associated with NMES treatment as a tool to minimize the effects of muscle disuse, as well as providing scientific support for the clinical use of this resource in the treatment in the light of the policies' health system.

Being tested
neuromuscular electrical stimulation
Keywords
muscular atrophy, electric stimulation therapy, intensive care units
Medical subject headings
COVID-19, Muscular Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • neuromuscular electrical stimulationDevice

    Also called NMES, transcutenaous electrical nerve stimulation

    application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions

Study groups in NCT04382378
Study groupRoleWhat they receive
control groupNo interventionGroup that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
50 electrically evoked contractionsExperimentalGroup that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
Receives: Device: neuromuscular electrical stimulation
100 electrically evoked contractionsExperimentalGroup that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
Receives: Device: neuromuscular electrical stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. cross sectional area of rectus femoris

    change of muscle wasting assessed by ultrassonogropahy

    Measured: from baseline to 14 days of therapy

  2. echointensity of rectus femoris

    change of echointensity of rectus femoris assessed by ultrassonography

    Measured: from baseline to 14 days of therapy

  3. muscle strength

    change of evoked peak torque of quadriceps femoris assesssed by unvolitional testing

    Measured: from baseline to 14 days of therapy

Secondary outcomes (2)
  1. Functional status

    Functional status assessed by IMS scale ranged from 0 to 10

    Measured: from baseline to 14 days of therapy

  2. ICU acquired weakness

    percent of patients that have muscle strength assessed by Medical Research Council Sum-Score (MRC-SS) lower than 48

    Measured: from baseline to 14 days of therapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2020
  2. Study start1 Feb 2021
  3. Primary completion30 Sep 2021 (estimated)
  4. Study completion31 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04382378
Sponsor's protocol ID
FAP042017
Acronym
NUMBERNMES
Status last verified
Mar 2021
First submitted
4 May 2020
Last updated
15 Mar 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing neuromuscular electrical stimulation in people with Mechanical Ventilation Complication and Muscle Weakness Condition, run by Escola Superior de Ciencias da Saude at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact VINICIUS ZACARIAS MALDANER D SILVA (6135462517, viniciusmaldaner@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

cross sectional area of rectus femoris (time frame: from baseline to 14 days of therapy). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in